Joseph P Kelleman
CIK 1629239 · View on SEC EDGAR ↗
First SEC filing: Feb. 17, 2015 · Latest: April 3, 2020
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Feb. 20, 2019 | MED | A | 355 | — | — | 2,355 Direct | +17.75% | Acquired | (price as of 2026-08-21) |
| Feb. 7, 2018 | MED | A | 1,250 | — | — | 1,250 Direct | — | Acquired | (price as of 2026-08-21) |
| Feb. 16, 2017 | MED | A | 1,250 | — | — | 1,250 Direct | — | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 7, 2018 | MED | Stock Options | Common Stock (1,250) | $66.68 | Feb. 7, 2028 | 1,250 | Acquired |
| Feb. 16, 2017 | MED | Stock Option | Common Stock (1,250) | $44.73 | Feb. 16, 2027 | 1,250 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 3 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
MED
CFO| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2020 | — | — | — | — | — | — | — | — |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.